Osteoporosis Drugs Market Size, Share, Growth Report 2030

Global Osteoporosis Drugs Market Overview     

The global Osteoporosis Drugs Market accounted for USD 13.7 Billion in 2020 and is expected to reach USD 17.92 Billion by 2028, growing at a CAGR of around 3.3% between 2021 and 2028.   

The rampant increase in the elderly population alongside changing lifestyles impacting bone health is anticipated to support the expansion of the osteoporosis drugs market over the years ahead. Aside from this, growing incidences of osteoporosis witnessed in post-menopausal women are probably going to amplify the osteoporosis drugs market expansion within the near future.

Seemingly, various complications & side-effects like nausea, irritable bowel syndrome, stomach ulcers, and heartburn are witnessed within the patients after consumption of osteoporosis drugs. These side-effects are predicted to restrain the industry expansion over the forthcoming years. Nevertheless, the persistent focus of industry players on developing new drugs which will help in minimizing the side-effects and high investments in R&D activities concerning new drug discovery are likely to make new growth opportunities for the osteoporosis drugs market, thereby normalizing the impact of hindrances on the osteoporosis drugs market

COVID-19 Impact Analysis  

Besides, the COVID-19 outbreak, there's a drastic increase in the demand for medical facilities across the world. The increasing corona cases across the world are forcing governments of developed and emerging countries to extend their patient handling capacities. COVID-19 has delayed and disrupted the treatment of many patients with osteoporosis; hence, the American Society for Bone and Mineral Research (ASBMR) set up a steering committee of bone specialists to manage the treatment of targeted disorders amid the pandemic. The improvement in fundraising related to Osteoporosis Drugs Market is another major factor that will positively impact the market growth.

Growth Factors

The global Osteoporosis Drugs Market is propelled owing to the increase in the obese and geriatric population since these individuals are more apt to numerous persistent diseases. So, the obese and geriatric population needs care with security and ease. Also, the market is essentially driven by a big rise in the prevalence of this disorder globally. This unprecedented rise within the prevalence resulted in the high demand for drugs in prophylaxis and treatment of osteoporosis thus widening the expansion potential over the approaching years. Moreover, the geriatric population possessing high susceptibility for osteoporosis is further presumed to propel the high demand.

Report Scope:  

Segment Analysis Preview  

Based on drug class the market is segmented into bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs). Key gender market covered under this study includes male and female. 

Rank ligand inhibitors are expected to grow at a lucrative CAGR during the forecast period. The high growth potential attained may be a consequence of positive patient outcomes related to rank ligand inhibitors. The positive patient outcomes are often attributed to significant improvements in bone metabolism. Rank ligand inhibitors also can be utilized in conjunction with other drugs to impart a synergistic effect in the overall treatment regime. The aforementioned factor is additionally predicted to be one of the key factors responsible to present lucrative opportunities. Other benefits concerning rank ligand Inhibitors like reduced cell bone turnover and increased bone mineral density, thereby implicating high demand.

Regional Analysis Preview

Regionally, North America has been leading the worldwide osteoporosis drugs market and is anticipated to continue on the dominant position within the years to return, states the market study. The presence of a well-established medical and healthcare infrastructure also as a drug delivery system is that the main factor behind the dominance of the North America osteoporosis drugs market. Additionally, sizable investments within the healthcare activities and favorable R&D policies of the govt towards the osteoporosis drug applications will further augment the osteoporosis drugs market growth.

Key Market Players & Competitive Landscape

The major players that are comprised in  Osteoporosis Drugs Market are  Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd.

The global  Osteoporosis Drugs Market is segmented as follows:

By Drug Class

• Bisphosphonates
• Calcitonin 
• Rank Ligand Inhibitors
• Parathyroid Hormone Therapy (PTH) 
• Selective Estrogen Receptor Modulators (SERMs)
• Others

By Gender

• Male
• Female

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa